image

REPORT SCOPE & OVERVIEW

Hepatitis B Vaccine Market size was valued at USD 7.9 billion in 2022 and is estimated to reach at USD 11.32 billion in 2030 and grow at a compound annual growth rate approx. CAGR of 4.6% predicted for the forecast period of 2023-2030.

The Hepatitis B vaccination (HBV) offers protection against the HBV and is a very safe and effective vaccine. It is a viral infection that targets the liver and can lead to both short-term and long-term health issues. By lowering the burden of Hepatitis B-related illnesses, the development and launch of the Hepatitis B vaccination have had a substantial influence on world health. The market for the Hepatitis B vaccine has grown significantly over the years, driven by growing healthcare costs, increased public knowledge of the value of immunisation, and government efforts to stop the spread of the disease. Various vaccinations, including recombinant vaccines, vaccines generated from plasma, and combination vaccines, are available on the market. Recombinant vaccinations: The sort of Hepatitis B vaccines that are most frequently used are recombinant vaccines. In order to manufacture viral antigens that can elicit an immune response, they are made utilising genetic engineering techniques. These immunisations are both extremely reliable and secure. Hepatitis B vaccinations made from plasma: These vaccines are made from the plasma of people who have become immune to the hepatitis B virus. Due to worries about the possible transfer of additional blood-borne illnesses, these vaccinations are currently less often utilised. Combination vaccinations: Combination vaccines offer protection against a number of illnesses with only one dose. Some vaccinations, such as those for diphtheria, tetanus, pertussis, and Haemophilus influenzae type (Hib), mix the Hepatitis B vaccine with other vaccines. Combination vaccines are practical and aid in increasing vaccination rates. The rising frequency of Hepatitis B infection, routine immunisation programmes, and the increased focus on reducing mother-to-child transmission are some of the factors driving the market for the Hepatitis B vaccine. Worldwide immunisation campaigns against Hepatitis B have been launched by governments and organisations. The Hepatitis B vaccination is advised for all babies as part of their standard immunisation plan by the World Health Organisation (WHO).

Hepatitis B Vaccine Market Revenue Analysis

MARKET DYNAMICS

DRIVERS  

  • Raising consciousness Government programmes

  • Increasing frequency technological progress.

Growing public awareness of the dangers and effects of hepatitis B infection has raised demand for vaccination, which is propelling the market's expansion. To stop the spread of Hepatitis B, several countries have adopted vaccination programmers and laws, which has increased vaccination rates and expanded the market.

There is a great need for vaccinations to prevent Hepatitis B since the infection rate is so high in some areas, particularly in Asia and Africa. The development of more potent and secure Hepatitis B vaccinations as a result of technological advancements in vaccine development and manufacturing has increased market demand.

RESTRAIN

  • Cost restrictions.

  • Poor healthcare infrastructure Reluctance to get vaccines.

Hepatitis B vaccination programmers may be more difficult to access and adopt in low-income nations due to the price of the vaccines. Poor healthcare infrastructure, particularly in rural regions, might make it difficult to administer and distribute Hepatitis B vaccinations effectively.

The adoption and uptake of Hepatitis B vaccinations can be impacted by vaccine reluctance and false information, which can have an influence on market growth.

OPPORTUNITY

  • Developing nations & vaccinations in combination.

  • Focus on mother-to-child transmission as a top priority.

In emerging markets where Hepatitis B infection rates are high and immunization programmers are being improved, there is a large scope for market development. There is a chance to increase vaccination coverage and decrease the number of injections necessary with the development of combination vaccines that provide protection against a variety of illnesses, including Hepatitis B. Market expansion is possible with initiatives to stop mother-to-child transmission of Hepatitis B through prenatal immunization.

CHALLENGES

  • Management of the cold chain & Supply and dissemination of vaccines.

  • Capacity for vaccine production.

The correct storage and transportation of hepatitis B vaccinations under certain temperature requirements can be difficult, especially in environments with limited resources. Accessibility of Hepatitis B vaccinations might be hampered by the difficulty of ensuring an adequate supply of vaccines and effective delivery networks to reach outlying locations. Manufacturers may find it difficult to meet the demand for Hepatitis B vaccinations on a worldwide scale while maintaining adequate production capacity.

IMPACT OF ONGOING RECESSION

The most common excuses given for not receiving a Hep B vaccination were lack of vaccine availability (32.6%), high vaccine cost (26.8%), worry about vaccine adverse effects (12.5%), lack of confidence in the quality of the vaccine (8.6%), awareness about vaccine locations (5.4%), and lack of time (2.9%). It is anticipated that the aggregate buying power would considerably affect emerging economies and is thought to be beneficial in many ways. The paper reveals how high inflation affects the long-term health of the global economy and offers information on the fiscal measures that may be taken to lessen its short-term effects on demand/supply, cash flow, and currency exchange. According to the Hepatitis B Vaccine Market research, there will be significant cost-push and demand-pull inflation in the future.

KEY MARKET SEGMENTS

  By Product End-User  

  • Single Antigen Vaccine

  • Combination Vaccine

By End users

  • Hospital

  • Clinics

  • Other

Hepatitis B Vaccine Market Segmentation Analysis

REGIONAL COVERAGE:

North America

  • USA

  • Canada

  • Mexico

Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • The Netherlands

  • Rest of Europe

Asia-Pacific

  • Japan

  • South Korea

  • China

  • India

  • Australia

  • Rest of Asia-Pacific

The Middle East & Africa

  • Israel

  • UAE

  • South Africa

  • Rest of the Middle East & Africa

Latin America

  • Brazil

  • Argentina

  • Rest of Latin American

REGIONAL ANALYSES

North America

Over the course of the forecast period, the North American market, which was valued at USD 2.60 billion in 2021, is anticipated to continue to dominate the worldwide market. Due to the rising prevalence of hepatitis B infections, the North American area now accounts for the biggest market share for hepatitis B vaccinations.

Europe

Europe is the second-most dominant area in terms of sales and market share. A sizable chunk of the hepatitis B vaccine industry was in Europe since European government authorities had implemented many regional action plans.

Key Players

The Key Players are GlaxoSmithKline, Gilead Science Inc., Merck & Co., Inc., Shenzhen Kangtai Biological Products Co., Ltd., Cyrus Poonawalla Group (Serum Institute of India Pvt.), Dynavax, Technologies Corporation, Sanofi, VBI Vaccines Inc., Meiji Group (KM Biologics), LG Chem Ltd., Indian Immunologicals Limited and others.

Gilead Science Inc-Company Financial Analysis

RECENT DEVELOPMENT

Sanofi:

Sanofi announced the acquisition of Bio Inc. in August 2021 in order to speed up the MRNA technology's adaptation for the study and creation of fresh vaccines. The company's R&D facility advanced as a result of this strategic purchase, and the pipeline of goods produced more effectively.

Gilead Science Inc:

Vir Biotechnology, Inc. and Gilead Science, Inc. worked together to create a novel combination medicine for the treatment of hepatitis B virus patients. This collaboration's primary goal is to assess several potential treatment combinations in the hopes of creating a new hepatitis B vaccine.

Hepatitis B Vaccine Market Report Scope:
Report Attributes Details
Market Size in 2022  US$ 7.9  Bn
Market Size by 2030  US$ 11.32 Bn
CAGR   CAGR of 4.6% From 2023 to 2030
Base Year  2022
Forecast Period  2023-2030
Historical Data  2020-2021
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Product End-User (Single Antigen Vaccine, Combination Vaccine)
• By End users (Hospital, Clinics, Others)
Regional Analysis/Coverage North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Company Profiles GlaxoSmithKline, Gilead Science Inc., Merck & Co., Inc., Shenzhen Kangtai Biological Products Co., Ltd., Cyrus Poonawalla Group (Serum Institute of India Pvt.), Dynavax, Technologies Corporation, Sanofi, VBI Vaccines Inc., Meiji Group (KM Biologics), LG Chem Ltd., Indian Immunologicals Limited and others
Key Drivers • Raising consciousness Government programmes
• Increasing frequency technological progress.
Market Opportunities • Developing nations & vaccinations in combination.
• Focus on mother-to-child transmission as a top priority.

 

Frequently Asked Questions

Ans: The CAGR Growth rate of Hepatitis B Vaccine Market is approx. CAGR 4.6% for the forecast period of 2023-2030.

Ans: The projected market size of Hepatitis B Vaccine Market at USD 7.9 billion in 2022 and is poised to reach at 11.32 billion in 2030

Ans: The major Key Players are GlaxoSmithKline, Gilead Science Inc., Merck & Co., Inc., Shenzhen Kangtai Biological Products Co., Ltd., Cyrus Poonawalla Group (Serum Institute of India Pvt.), Dynavax, Technologies Corporation, Sanofi, VBI Vaccines Inc., Meiji Group (KM Biologics), LG Chem Ltd., Indian Immunologicals Limited and others.

Ans: The high incidence of hepatitis B infection, along with the expanding population at risk, particularly newborns and healthcare professionals, is responsible for the north American hepatitis B vaccine market over 40.8% revenue share in 2022 and is projected to increase at a significant rate through 2030.

Ans: It is anticipated that widespread product approvals and high demand for mass immunization would accelerate the adoption of these products.

Table of Contents


1. Introduction
1.1 Market Definition 
1.2 Scope
1.3 Research Assumptions


2. Research Methodology


3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges 


4. Impact Analysis
4.1 Impact of ongoing Recession 
4.1.1 Introduction
4.1.2 Impact on major economies
4.1.2.1 US
4.1.2.2 Canada
4.1.2.3 Germany
4.1.2.4 France
4.1.2.5 United Kingdom
4.1.2.6 China
4.1.2.7 Japan
4.1.2.8 South Korea
4.1.2.9 Rest of the World


5. Value Chain Analysis
 

6. Porter’s 5 forces model


7. PEST Analysis


8. Hepatitis B Vaccine Market, By Type
8.1 Single Antigen Vaccine
8.2 Combination Vaccine


9. Hepatitis B Vaccine Market, By End-User
9.1    Hospital
9.2 clinics
9.3 Others


10. Regional Analysis
10.1 Introduction
10.2 North America
10.2.1 North America Hepatitis B Vaccine Market, by country
10.2.2North America Hepatitis B Vaccine Market by Type
10.2.3 North America Hepatitis B Vaccine Market by End-User 
10.2.4 USA    
10.2.4.1 USA Hepatitis B Vaccine Market by Type
10.2.4.2 USA Hepatitis B Vaccine Market by End-User     
10.2.7 Canada
10.2.7.1 Canada Hepatitis B Vaccine Market by Type    
10.2.7.2 Canada Hepatitis B Vaccine Market by End-User 
10.2.8 Mexico
10.2.8.1 Mexico Hepatitis B Vaccine Market by Type    
10.2.8.2 Mexico Hepatitis B Vaccine Market by End-User 
10.3 Europe 
10.3.1 Europe Hepatitis B Vaccine Market by country
1.3.3.2 Europe Hepatitis B Vaccine Market by Type    
10.3.3 Europe Hepatitis B Vaccine Market by End-User 
10.3.6 Germany
10.3.6.1 Germany Hepatitis B Vaccine Market by Type    
10.3.6.2 Germany Hepatitis B Vaccine Market by End-User 
10.3.7 UK
10.3.7.1 UK Hepatitis B Vaccine Market by Type    
10.3.7.2 UK Hepatitis B Vaccine Market by End-User 
10.3.8 France
10.3.8.1 France Hepatitis B Vaccine Market by Type
10.3.8.2 France Hepatitis B Vaccine Market by End-User 
10.3.9 Italy
10.3.9.1 Italy Hepatitis B Vaccine Market by Type
10.3.9.2 Italy Hepatitis B Vaccine Market by End-User 
10.3.10 Spain
10.3.10.1 Spain Hepatitis B Vaccine Market by Type    
10.3.10.2 Spain Hepatitis B Vaccine Market by End-User  
10.3.11 The Netherlands
10.3.11.1 Netherlands Hepatitis B Vaccine Market by Type    
10.3.11.2 Netherlands Hepatitis B Vaccine Market by End-User 
10.3.12 Rest of Europe
10.3.12.1 Rest of Europe Hepatitis B Vaccine Market by Type
10.3.12.2 Rest of Europe Hepatitis B Vaccine Market by End-User 
10.4 Asia-Pacific
10.4.1 Asia Pacific Hepatitis B Vaccine Market by country
10.4.2 Asia Pacific Hepatitis B Vaccine Market by Type
10.4.3 Asia Pacific Hepatitis B Vaccine Market by End-User 
10.4.6 Japan
10.4.6.1 Japan Hepatitis B Vaccine Market by Type    
10.4.6.2 Japan Hepatitis B Vaccine Market by End-User 
10.4.7 South Korea
10.4.7.1 South Korea Hepatitis B Vaccine Market by Type
10.4.7.2 South Korea Hepatitis B Vaccine Market by End-User 
10.4.8 China
10.4.8.1 China Hepatitis B Vaccine Market by Type    
10.4.8.2 China Hepatitis B Vaccine Market by End-User     
10.4.9 India
10.4.9.1 India Hepatitis B Vaccine Market by Type    
10.4.9.2 India Hepatitis B Vaccine Market by End-User 
10.4.10 Australia
10.4.10.1 Australia Hepatitis B Vaccine Market by Type
10.4.10.2 Australia Hepatitis B Vaccine Market by End-User     
10.4.11 Rest of Asia-Pacific
10.4.11.1 APAC Hepatitis B Vaccine Market by Type    
10.4.11.2 APAC Hepatitis B Vaccine Market by End-User     
10.5 The Middle East & Africa
10.5.1 The Middle East & Africa Hepatitis B Vaccine Market by country
10.5.2 The Middle East & Africa Hepatitis B Vaccine Market by Type    
10.5.3 The Middle East & Africa Hepatitis B Vaccine Market by End-User 
10.5.6 Israel
10.5.6.1 Israel Hepatitis B Vaccine Market by Type    
10.5.6.2 Israel Hepatitis B Vaccine Market by End-User     
10.5.7 UAE
10.5.7.1 UAE Hepatitis B Vaccine Market by Type
10.5.7.2 UAE Hepatitis B Vaccine Market by End-User 
10.5.8 South Africa
10.5.8.1 South Africa Hepatitis B Vaccine Market by Type
10.5.8.2 South Africa Hepatitis B Vaccine Market by End-User 
10.5.9 Rest of Middle East & Africa
10.5.9.1 Rest of Middle East & Asia Hepatitis B Vaccine Market by Type
10.5.9.2 Rest of Middle East & Asia Hepatitis B Vaccine Market by End-User 
10.6 Latin America
10.6.1 Latin America Hepatitis B Vaccine Market by country
10.6.2 Latin America Hepatitis B Vaccine Market by Type
10.6.3 Latin America Hepatitis B Vaccine Market by End-User 
10.6.6 Brazil
10.6.6.1 Brazil Hepatitis B Vaccine Market by Type
10.6.6.2 Brazil Africa Hepatitis B Vaccine Market by End-User 
10.6.7 Argentina
10.6.7.1 Argentina Hepatitis B Vaccine Market by Type
10.6.7.2 Argentina Hepatitis B Vaccine Market by End-User 
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America Hepatitis B Vaccine Market by Type
10.6.8.2 Rest of Latin America Hepatitis B Vaccine Market by End-User 


12 Company profile
12.1 Eli Lilly and Company, 
12.1.1 Market Overview
12.1.2 Financials
12.1.3 Treatment/Services/Offerings
12.1.4 SWOT Analysis
12.1.5 The SNS View
12.2 Celgene Corporation
12.2.1 Market Overview
12.2.2 Financials
12.2.3 Treatment/Services/Offerings
12.2.4 SWOT Analysis
12.2.5 The SNS View
12.3 F. Hoffmann-La Roche AG
12.3.1 Market Overview
12.3.2 Financials
12.3.3 Treatment/Services/Offerings
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.4 Amgen Inc.
12.4.1 Market Overview
12.4.2 Financials
12.4.3 Treatment/Services/Offerings
12.4.4 SWOT Analysis
12.4.5 The SNS View
12.5 Novartis AG.
12.5.1 Market Overview
12.5.2 Financials
12.5.3 Treatment/Services/Offerings
12.5.4 SWOT Analysis
12.5.5 The SNS View
12.6 Pharmacy Biotech Inc.
12.6.1 Market Overview
12.6.2 Financials
12.6.3 Treatment/Services/Offerings
12.6.4 SWOT Analysis
12.6.5 The SNS View
12.7 Clovis Oncology.
12.7.1 Market Overview
12.7.2 Financials
12.7.3 Treatment/Services/Offerings
12.7.4 SWOT Analysis
12.7.5 The SNS View
12.8 Teva Pharmaceutical Industries Ltd.
12.8.1 Market Overview
12.8.2 Financials
12.8.3 Treatment/Services/Offerings
12.8.4 SWOT Analysis
12.8.5 The SNS View
12.9 Merck & Co., Inc. 
12.9.1 Market Overview
12.9.2 Financials
12.9.3 Treatment/Services/Offerings
12.9.4 SWOT Analysis
12.9.5 The SNS View
12.10 Pfizer, Inc.
12.10.1 Market Overview
12.10.2 Financials
12.10.3 Treatment/Services/Offerings
12.10.4 SWOT Analysis
12.10.5 The SNS View
13. Competitive Landscape
13.1 Competitive Benchmarking
13.2 Market Share analysis
13.3 Recent Developments


14. Use Case and Best Practices


15. Conclusion

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.

Start a Conversation

Hi! Click one of our member below to chat on Phone